The increasing costs of medicines and their implications for patients, physicians and the health system

被引:4
作者
Ghinea, Narcyz [1 ,2 ]
机构
[1] Macquarie Univ, Eth & Agcy Res Ctr, Dept Philosophy, Sydney, NSW, Australia
[2] Macquarie Univ, Fac Arts, Dept Philosophy, Level 7,25B Wallys Walk, Sydney, NSW 2109, Australia
关键词
pharmaceuticals; funding; reimbursement; drug development; high cost; ANTICANCER DRUGS; ACCESS;
D O I
10.1111/imj.16370
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Most new medicines entering the market are high-cost speciality drugs. These drugs can cost tens to hundreds of thousands of dollars per course of treatment and in some cases millions of dollars per dose. Approximately half of all spending on medicines is projected to target only 2-3% of patients, raising important questions about resource allocation. While there is no doubt that breakthrough innovations have transformed clinical care in some disciplines, it is also true that cost is becoming one of the primary barriers to treatment access and that many new medicines do not provide value commensurate with their prices. This article examines pricing trends, the reasons for high prices and their implications for access and clinical practice.
引用
收藏
页码:545 / 550
页数:6
相关论文
共 44 条
[1]  
[Anonymous], ABC NEWS
[2]  
[Anonymous], WYD GRASSL SOV INV F
[3]  
[Anonymous], INF WORLDS BIGG PLAY
[4]  
[Anonymous], Adherence to long-term therapies: evidence for action
[5]  
[Anonymous], 2018, Australia's Health 2018: In Brief, How Do We Use Health Care
[6]  
[Anonymous], HLTH EXP AUSTR 2020
[7]  
[Anonymous], FAIR PRIC FOR 2021
[8]  
Australian Bureau of Statistics, PAT EXP 2021 22 FIN
[9]  
Beasley D., US NEW DRUG PRICE EX
[10]   Documenting the financialisation of the pharmaceutical industry [J].
Busfield, Joan .
SOCIAL SCIENCE & MEDICINE, 2020, 258